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Abstract
Background: The urokinase plasminogen activator receptor (uPAR) is associated with poor prognosis in oral squamous cell
carcinoma (OSCC), and increased expression of uPAR is often found at the invasive tumour front. The aim of the current
study was to elucidate the role of uPAR in invasion and metastasis of OSCC, and the effects of various tumour
microenvironments in these processes. Furthermore, we wanted to study whether the cells’ expression level of uPAR
affected the activity of gelatinolytic enzymes.
Methods: The Plaur gene was both overexpressed and knocked-down in the murine OSCC cell line AT84. Tongue and skin
tumours were established in syngeneic mice, and cells were also studied in an ex vivo leiomyoma invasion model. Soluble
factors derived from leiomyoma tissue, as well as purified extracellular matrix (ECM) proteins, were assessed for their ability
to affect uPAR expression, glycosylation and cleavage. Activity of gelatinolytic enzymes in the tissues were assessed by
in situ zymography.
Results: We found that increased levels of uPAR did not induce tumour invasion or metastasis. However, cells expressing
low endogenous levels of uPAR in vitro up-regulated uPAR expression both in tongue, skin and leiomyoma tissue. Various
ECM proteins had no effect on uPAR expression, while soluble factors originating from the leiomyoma tissue increased both
the expression and glycosylation of uPAR, and possibly also affected the proteolytic processing of uPAR. Tumours with high
levels of uPAR, as well as cells invading leiomyoma tissue with up-regulated uPAR expression, all displayed enhanced
activity of gelatinolytic enzymes.
Conclusions: Although high levels of uPAR are not sufficient to induce invasion and metastasis, the activity of gelatinolytic
enzymes was increased. Furthermore, several tumour microenvironments have the capacity to induce up-regulation of
uPAR expression, and soluble factors in the tumour microenvironment may have an important role in the regulation of
posttranslational modification of uPAR.
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Introduction
Oral squamous cell carcinoma (OSCC) is the most common
malignancy of the oral cavity [1,2], with a poor 5-year survival rate
[2–4]. Urokinase-type plasminogen activator (uPA), a member of
the plasminogen activation (PA) system, and its receptor, the
urokinase plasminogen activator receptor (uPAR), have both been
linked to poor prognosis in several cancer types [5–7], including
OSCC [8–10]. The PA system consists of plasminogen which is
the precursor of the active serine protease plasmin, its two
activators (tissue-type plasminogen activator (tPA) and uPA),
uPAR, as well as the inhibitors plasminogen activator inhibitor-1
(PAI-1) and PAI-2. uPA is secreted in its inactive pro-form (pro-
uPA), and is readily activated in a feed-back-loop by plasmin upon
binding to uPAR. uPAR is a highly glycosylated protein consisting
of three homologous domains (D1, D2, and D3) and is linked to
the plasma membrane via a GPI-anchor [11]. Plasmin functions as
a broad spectrum protease that is able to degrade several
extracellular matrix (ECM) proteins including gelatin [12], and
activate latent growth factors and matrix metalloproteases (MMPs)
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[13]. Furthermore, plasmin, uPA, trypsin, chymotrypsin, cathepsin
G, elastase and some MMPs are all able to cleave uPAR in the
linker region between D1 and D2 [14–17]. This disrupts the
receptor’s ability to bind uPA [18] in what is thought to be a
natural regulation of the uPA-mediated proteolytic activity [19].
Cleavage of human uPAR can also expose the chemotactic
SRSRY peptide (uPAR88–92) residing between D1 and D2 [20].
The SRSRY peptide can interact with the N-formyl peptide
receptor (FPR), FPR-like 1 (FPRL1) and FPRL2 leading to
directional cell migration [21–23]. Lastly, the GPI-anchor of
uPAR may be cleaved by several phospholipases, releasing the
soluble form of uPAR (suPAR), but also soluble uPAR D2+D3
either with or without the SRSRY peptide [17,19,24–26]. SuPAR
and soluble cleaved forms of uPAR detected in either tissue and
biological fluids may indicate an active PA-system and have been
associated with poor prognosis in soft-tissue sarcoma, breast-,
colorectal-, lung-, ovarian- and prostate cancer [27–38].
We previously observed that low expression of uPAR is
associated with a favourable outcome in early stage OSCC [10].
Therefore, in the current study we wanted to elucidate the role of
uPAR in invasive and metastatic tumour growth, and furthermore
study how the tumour microenvironment participates in this
process. To this end, tongue and skin tumours were established of
the mouse OSCC cell line AT84 expressing either low uPAR
levels or over-expressing uPAR. The cells were also analysed as
they invaded the tissue of the leiomyoma invasion model [39].
Increased levels of uPAR did not lead to increased invasion or
metastasis of these cells. However, the endogenous expression of
uPAR was up-regulated in the initially low-uPAR expressing cells
at the tumour stroma border in vivo, and as they invaded deep
into the leiomyoma tissue. Analysis of gelatinolytic activity
revealed that cells expressing high uPAR levels had an increased
ability to activate gelatinolytic enzymes. When cells were
stimulated in vitro with soluble factors derived from the leiomy-
oma stroma, an increase in the apparent molecular weight of the
uPAR protein was observed, possibly due to increased glycosyl-
ation and/or an alteration in uPAR cleavage.
Together these results show that the tumour microenvironment
can affect both the expression and posttranslational modifications
of uPAR in the tumour cells, and thereby influence the activity of
the gelatinolytic enzymes.
Results
Overexpression of uPAR in the murine AT84 cell line
uPAR expression is often increased in OSCCs at the invasive
front [40], suggesting that it may have a role in invasion and
metastasis. To better understand the role of uPAR in OSCC
progression, cells expressing high and low levels of uPAR were
generated. The murine OSCC cell line AT84 [41] was selected for
this study, as it expresses low endogenous levels of uPAR in culture
(figure 1a), and allowed the use of a syngeneic mouse model with
immunocompetent mice. Single cell clones expressing high levels
of uPAR were generated, and two clones were chosen for further
study (uPAR1 expressing very high levels of uPAR, and uPAR2
expressing moderate levels of uPAR, figure 1a). Two single cell
clones containing only the empty vector were selected as controls
(EV1 and EV2), expressing low endogenous levels of uPAR as
shown by Western blotting (figure 1a). Recombinant soluble His-
tagged uPAR (rmuPAR) was loaded as a positive control, which
(due to being produced in insect cells) is less glycosylated, and
therefore has a lower MW than uPAR expressed by the AT84 cells
(figure 1a). Cell surface localization of uPAR was verified by
Western blotting of membrane fractions (figure 1b), and with flow
cytometry on non-permeabilized cells (figure 1c). Plaur mRNA
levels (figure 1d) reflected the uPAR protein expression levels
(figure 1a), and all clones expressed Plau mRNA (figure 1e), as
analysed by RT-qPCR. Bands with similar size to recombinant
active high molecular weight (HMW)-uPA were detected when the
conditioned medium was analysed by gelatin-plasminogen zymo-
graphy, and not by gelatin zymography, indicating that the clones
express similar levels of uPA (figure 1f - full gel images can be
viewed in figure S1). Plasminogen mRNA levels varied among the
clones, with EV1 displaying the highest expression, and EV2 the
lowest (figure 1g).
Induction of endogenous uPAR expression in vivo
In order to analyse the effects of various levels of uPAR on
tumour invasiveness and metastasis, cells expressing either high-
(uPAR1 and uPAR2) or low endogenous- (EV1 and EV2) levels of
uPAR were injected into the tongue of immunocompetent mice.
Tumours were harvested already after 14 days due to rapid
tumour growth, although not all mice developed tumours. None of
the tumours displayed infiltrative growth and were rounded with
clear and defined borders (figure 2a–b). No metastases were
detected in lymph nodes, livers or lungs, showing that neither of
these clones displayed aggressive behaviour in vivo within the limit
of 14 days of tumour growth.
Tumours were ZBF-fixed and tissue sections were IHC stained
and analysed for the presence of uPAR (figure 2c–h). uPAR
staining was mostly seen in the tumour cells both at the cell
membrane and in the cytoplasm. To verify the specificity of the
uPAR antibody, control experiments were performed where the
anti-uPAR antibody was pre-absorbed with recombinant uPAR.
IHC staining using the pre-absorbed uPAR-antibody demonstrat-
ed that the staining was not due to unspecific binding of the
antibody (file S1 and figure S2). Tongue tumours of uPAR1 cells,
which in culture express high levels of uPAR, had an average
staining index (SI) of 6.25 (out of max 9) and were more positive
than tumours of uPAR2 cells (SI = 4.22) (figure 2i) that in culture
expressed moderate levels of uPAR. Surprisingly, tumours
generated from the EV-cells also displayed a moderately strong
staining for uPAR. The EV1 (figure 2e) and EV2 (figure 2g)
tongue tumours had an average SI of 3.25 and 4.60, respectively,
and were therefore considered to have moderate expression of
uPAR similar to uPAR2 (figure 2i). The staining was most
prominent in the periphery of the EV-tumours (figure 2c),
suggesting that the tumour microenvironment is involved in the
up-regulation of uPAR expression.
A similar induction of uPAR expression was observed in the
EV-cells when the cells were injected subcutaneously (figure S3),
indicating that different types of tumour microenvironments can
induce endogenous uPAR expression. The skin tumours, like the
tongue tumours, also had clear and defined borders, displayed no
infiltrative growth (see figure S3a–b) or metastases. The skin
tumours generally displayed weaker uPAR staining in comparison
to the tongue tumours with an average SI of 2.44 and 3.90 for the
EV1 and EV2 tumours respectively (see figure S3i). This was
similar to uPAR2 with an SI of 4.00. The uPAR1 tumours showed
the highest SI of 6.38 (see figure S3i).
Knock-down of uPAR expression in AT84 cells
Due to the endogenous up-regulation of uPAR in vivo, shRNA
was transfected into the cells to knock-down and keep uPAR levels
low. Five different shRNA constructs were tested by transient
transfection of uPAR1 (see figure S4a) cells. New single cell clones
were generated based on the EV1 or uPAR1 cells as shown in the
flow chart (figure 3a). As controls, EV1 and uPAR1 cells were
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transfected with either empty vector (EV) or non-target shRNA
(NT). The selected EV1-NT, EV1-sh3 and EV1-sh5 single cell
clones all displayed low or undetectable levels of uPAR on
Western blots (figure 3b). The selected control cells uPAR1-EV
and uPAR1-NT displayed some reduction in uPAR levels when
compared to the uPAR1 cells, but a much greater reduction was
obtained in the uPAR1-sh3, uPAR1-sh4 and uPAR1-sh5 knock-
down cells (figure 3b). A mixed population of shRNA bulk
transfected cells (uPAR-sh-B) was also generated, though the
efficiency of the uPAR knock-down was less than that obtained
with single cell cloning (see figure S4b and file S2). Thus, the single
cell clones were therefore chosen for the subsequent experiments.
Figure 1. Expression of murine Plaur in AT84 cells. In vitro characterization of AT84 cells stably transfected with either empty vector (EV) or a
vector containing cDNA encoding murine uPAR (Plaur). A: Western blot analysis of whole cell lysates using a polyclonal anti-murine uPAR antibody
(AF534). A total of 7.5 ng of recombinant murine uPAR (rmuPAR) was loaded as a positive control. Re-probing for b-actin was used as a loading
control. B: Western blot analysis of cellular membrane fractions using a polyclonal anti-murine uPAR antibody (AF534). Total protein was measured
per sample and 53.5 mg of protein was loaded per lane. A and B: Images were cropped, as no additional bands were detectable. C: FACS analysis of
non-permeabilized cells using a polyclonal anti-murine uPAR antibody (AF534). Alexa Fluor 488 anti-goat secondary antibody (A11055) was used as
the secondary antibody. The quantified mean Alexa 488 fluorescence signal per cell line is presented in the panel to the right. D and E: Relative Plaur
mRNA (uPAR) (D) or Plau mRNA (uPA) (E) expression levels as analysed using RT-qPCR. All expression levels were normalized to the expression of the
reference genes Trfc and b-actin. Error bars represent the standard error of mean (+SEM) and N= 3. One-way ANOVA; *p,0.05. F: Plasminogen-
gelatin (upper panel) and gelatin (lower panel) zymography analysis of conditioned medium of cells cultured for 24 hours in SFM. HMW-uPA and
mPLM (mouse plasmin) were loaded as positive controls. The images were cropped to size. G: Relative Plasminogen mRNA (Plg) expression levels as
analysed using RT-qPCR. Error bars represent standard error of mean (+SEM) and N=3.
doi:10.1371/journal.pone.0105929.g001
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In vivo tongue tumours of uPAR knock-down cells
Tongue tumours were generated with the new clones in order to
analyse the effects on invasiveness and uPAR expression in the
presence of Plaur-targeting shRNA. For the analysis of the
tumours, the EV1-sh3 and EV1-sh5 tumours were grouped
together as EV1-sh, and the uPAR1-sh4 and uPAR1-sh5 tumours
were grouped together as uPAR1-sh. IHC staining revealed that
the uPAR levels were kept low in the EV1-sh tumours (figure 4a).
The average SI of the uPAR staining is presented in the graph in
figure 4e. The EV1-sh tumours had an average SI of 1.55 and
showed considerably lower levels of uPAR than the EV1 tumours
(SI = 3.25), and a significantly lower expression than the uPAR1-
NT tumours (figure 4b) which had an average SI of 7 (figure 4e).
The uPAR1-sh tumours (figure 4c) displayed great variations in
uPAR protein expression, resulting in a large standard error of
mean (figure 4e). Tumours from the EV1-sh cells (figure 4d), as
well as tumours from the control transfected cells (uPAR1-NT)
(data not shown), displayed no signs of infiltrative or metastatic
growth. Taken together, although shRNA mediated knock-down
of uPAR enabled generation of tumours with significantly different
levels of uPAR, no difference in tumour invasiveness or metastasis
could be detected.
Leiomyoma stroma is a strong inducer of uPAR
expression in invading cells
In order to more specifically analyse the effects of the tumour
microenvironment on uPAR expression and invasive capacity, the
leiomyoma invasion model was used [39]. The human neoplastic
leiomyoma tissue is rich in collagen I, -III, -IV, and laminins, and
this organotypic invasion model has proven to be a good model for
local invasion, mimicking the hypoxic tumour environment [42].
Cells expressing either high- or low levels of uPAR were seeded on
top of the leiomyoma tissue discs and incubated for 7 or 14 days,
whereupon the leiomyoma tissue was ZBF-fixed. Tissue sections
were stained with H/E and total invasion was scored (file S3). No
differences in invasion that could be directly attributed to the
uPAR expression status of the cells were found (figure S5). In order
to determine the uPAR expression levels in the cells invading the
leiomyoma tissue, they were IHC stained for uPAR (figure 5).
Negative controls, with no added cells, gave no uPAR staining
(results not shown). The high-uPAR expressing clones (uPAR1-EV
and uPAR1-NT) remained uPAR positive throughout the
experiment regardless of whether the cells were located on top
or invading into the tissue (figure 5, right panels). In contrast, the
low uPAR expressing cells (EV1-sh3 and EV1-sh5) located on top
of the leiomyoma tissue remained uPAR negative for the duration
of the experiment, while invasive cells gradually increased the
uPAR protein levels with time despite the presence of shRNA
constructs (figure 5, left panels). Thus, invading cells were strongly
induced to express uPAR, further implicating the tumour
microenvironment in regulation of uPAR expression.
Figure 2. Tumour microenvironment induced uPAR protein
expression in tongue tumours. Tumour growth pattern and uPAR
protein levels in tongue tumours generated from the EV1, EV2, uPAR1
and uPAR2 cells. A–B: Representative images depicting the tumour
growth pattern at the tumour-stroma interface in hematoxylin/eosin
stained EV1 (A) and uPAR1 (B) tumours. Images were recorded at 10x
magnification. C–D: Representative images depicting the IHC uPAR
staining of the EV1 (C) or uPAR1 tumours (D). Images were recorded at
4x magnification. E–H: The images show high power magnification (20x
magnifications) of the EV1 (E), uPAR1 (F), EV2 (G) and uPAR2 (H)
tumours IHC stained for uPAR protein. Positive uPAR staining is seen as
brown colour, and counterstaining was done with haematoxylin. I: The
average staining index (SI) of the uPAR staining in the tumours.
Maximum obtainable score is 9. The error bars shows the +SEM.
N= number of tumours; EV1, N= 8/10; EV2, N = 5/10; uPAR1, N= 4/10;
uPAR2 N= 9/10. One-way ANOVA; **p,0.01, *p,0.05. T = Tumours,
S = Stroma.
doi:10.1371/journal.pone.0105929.g002
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Soluble factors from the leiomyoma tissue mediate a
time dependent induction of uPAR levels
The up-regulated expression of uPAR seen in the EV-cells could
be due to either soluble or insoluble factors present in the tumour
microenvironment. Many different growth factors, cytokines and
chemokines are known to up-regulate uPAR expression in various
cell types [43–46]. To analyse whether soluble factors from the
leiomyoma could explain the increased expression of uPAR, the
freeze-dried leiomyoma tissue was rehydrated in serum free
medium (SFM) which was subsequently used as conditioned
growth medium for the cells in culture. After 24 (figure 6a) or 48
hours (figure S6), the cells were harvested and analysed for uPAR
expression by Western blotting. uPAR levels were not notably
increased in the uPAR1-EV and uPAR1-NT cells, although the
size of the expressed uPAR was strikingly increased (figure 6a).
Little uPAR could be detected in the low uPAR expressing clones
(EV1-NT, EV1-sh3 and EV1-sh5) after 24 or 48 hours of
incubation with leiomyoma conditioned medium (LCM). There
was, however, a small induction of uPAR expression in the
uPAR1-sh3 and uPAR1-sh5 clones after 24 hours (figure 6a).
Incubating the cells in LCM for 48 hours induced a marked
increase in uPAR expression levels in all the uPAR1-sh cells (figure
S6), indicating that these cells more readily turn on the uPAR
expression, as also seen in vivo (figure 4).
To further test whether ECM proteins known to be present in
the tumour stroma could regulate the expression of uPAR, EV1-
NT, EV1-sh3, uPAR1-NT and uPAR1-sh4 cells were seeded on
different ECM substrates. Western blot analysis showed that none
of the substrates induced detectable levels of uPAR in the EV1-
NT, EV1-sh3 and uPAR1-sh4 cells (results not shown), whereas
uPAR1-NT cells displayed equal levels of uPAR on all substrates
tested (figure 6b).
To investigate whether the size change induced by the LCM
was due to increased glycosylation, lysates of cells that had been
treated with LCM or SFM were deglycosylated by PNGase F
treatment (figure 6c). Western blot analysis using the polyclonal
anti-uPAR antibody showed that cells treated with either SFM or
LCM expressed three distinct bands after deglycosylation
(figure 6c, indicated with the numbers 1, 2 and 3). Band no. 1
corresponds to the size previously reported for full length
deglycosylated uPAR (approximately 35 kDa). Band no. 2
corresponds to the previously reported size of deglycosylated
uPAR D2+D3 (approximately 25 kDa) [14]. Band no. 3 could
possibly correspond to either D1 of uPAR or GPI-anchored D3 of
uPAR (approximately 18 kDa) [16,19]. Hence, the increased size
of uPAR after incubation with LCM was either due to increased
glycosylation, or possibly due to less cleavage of full-length uPAR.
Analysis of the bands by mass spectrometry revealed that uPAR-
peptides were present in both band no. 1 as well as in band no. 2
(results not shown). No uPAR-peptides could be detected in the
18 kDa band. To verify that bands no. 1 and 2 represent full-
length and cleaved uPAR, respectively, cells were incubated with
the uPA inhibitor BC11 hydrobromide. uPA is reported to cleave
the linker region between D1 and D2 of uPAR [14], hence
producing uPAR D2+D3. Cells expressing high levels of uPAR
were incubated in the presence of BC11 hydrobromide for 72
hours, harvested and analysed by Western blot using the anti-
uPAR antibody (file S4 and figure S7). By inhibiting uPA, band
Figure 3. Knock-down of uPAR expression in AT84 cells. shRNA knock-down of Plaur in AT84 cells. A: Flow chart showing the generation of
the single cell clones. B:Western blot analysis of whole cell lysates from the single cell clones stably transfected with either shRNA-constructs (shRNA
3= sh3, shRNA 4= sh4 or shRNA 5= sh5) targeting Plaur or constructs containing non-target shRNA (NT) or the empty vector (EV). uPAR was detected
using a polyclonal anti-murine uPAR antibody (AF534). Re-probing for b-actin was used as a loading control. Images were cropped, as no additional
bands were detected in the blot.
doi:10.1371/journal.pone.0105929.g003
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no. 1 became stronger than band no. 2, indicating that the two
bands indeed represent full-length and cleaved uPAR, respectively.
Taken together, soluble factors isolated from the leiomyoma
tissue induced an increase in uPAR levels in a time dependent
manner. In addition, the LCM induced an increase in the size of
uPAR probably due to increased glycosylation, and possibly also
altered the cleavage of uPAR.
Increased activity of gelatinolytic enzymes at the invasive
front
Breakdown of surrounding stroma is a key step in the process of
tumour invasion and metastasis. Plasmin, in addition to gelatinases
such as MMP-2 and MMP-9, are known to be potent gelatin
degrading enzymes. Furthermore, gelatinolytic enzymes have
many non-ECM substrates which might have a role in cancer
progression. To assess whether the regulation of uPAR expression
affects the cell’s ability to activate gelatinolytic enzymes, the
tumours were analysed by in situ zymography. Sections of tongue
tumours generated from EV1-sh3, EV1-sh5 and uPAR1-NT were
incubated with dye quenched (DQ)-gelatin and analysed by
confocal microscopy. The results showed a marked increase in
active gelatinolytic enzymes in the tumours expressing high levels
of uPAR (figure 7a). Auto-fluorescence was undetectable as
assessed by incubating the sections at 220uC for 2 hours
immediately after the substrate was added (results not shown).
The gelatinolytic activity was quantified using Volocity software
(figure 7b), and a statistically significant difference in gelatinolytic
activity was found between the EV1-sh and the uPAR1-NT
tumours. In order to distinguish between gelatinolytic activity of
metalloproteases and activity from other gelatin degrading
enzymes such as plasmin, the metalloprotease-inhibitor EDTA
was added. EDTA reduced the activity to some extent, though
with varying degrees from tumour to tumour (figure 7b). Thus the
enzymes contributing to the gelatinolytic activity are a mixture of
metalloproteases and non-metalloproteases. Tumours generated
from uPAR1 and EV1 cells (figure 2) were also analysed by in situ
zymography (figure S8). Also in these tumours the gelatinolytic
activity was significantly increased in the uPAR1 tumours
compared to the EV1 tumours though the difference was not as
clear, possibly due to the up-regulation of uPAR in the EV1 cells
in vivo (see figure 2a).
In addition, gelatinolytic activity was assessed in high- and low
uPAR-expressing cells invading the leiomyoma tissue (figure 8).
There was no significant difference between the clones, but the
gelatinolytic activity was generally stronger in the invading cells
compared to the non-invading cells. This is in accordance with the
finding that all invading cells showed elevated uPAR expression
regardless of the uPAR level of the clones in vitro (see figure 5).
When EDTA was added, only the gelatinolytic activity of the non-
invading cells, where uPAR levels were low, was reduced.
Meanwhile, there was no inhibition seen in the gelatinolytic
activity of the invading cells which had high uPAR expression.
Taken together, tumour cells with increased uPAR levels also
displayed increased ability to activate gelatinolytic enzymes.
Discussion
uPAR and uPA have both been linked to poor prognosis for
several cancer types, where they are thought to play a role in
invasion and metastasis [5–7]. In light of this, the main focus of the
current study was to elucidate the role of uPAR expression in
Figure 4. In vivo tongue tumours of EV1 and uPAR1 knock-down cells. IHC uPAR staining and growth pattern of tongue tumours generated
from the EV1 and uPAR1 cells containing either shRNA targeting uPAR (EV1-sh and uPAR1-sh), or non-targeting shRNA (uPAR1-NT). A–C: IHC uPAR
staining of EV1-sh (A), uPAR1-NT (B) and uPAR1-sh (C) tumours, respectively. Images were recorded at 20x magnifications. D: Representative image
depicting the tumour growth pattern at the tumour-stroma interface in hematoxylin/eosin stained EV1-sh. E: The average SI of the uPAR staining in
the tumours, with the maximum obtainable score of 9. The error bars shows the +SEM. N= number of tumours; EV1, N = 8/10; EV1-sh, N= 11/16;
uPAR1, N= 4/10; uPAR1-NT, N= 3/8; uPAR1-sh, N= 4/16. One-way ANOVA; **p,0.01, *p,0.05. T = Tumour, S = Stroma.
doi:10.1371/journal.pone.0105929.g004
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OSCC. To this end, uPAR was first overexpressed in the murine
OSCC cell line AT84 (figure 1), and cells were analysed in vitro in
cell culture, in vivo as tongue and skin tumours (figure 2 and
figure S3), and ex vivo when invading leiomyoma tissue (figure 5
and 8). The main finding was that the uPAR levels of the tumour
cells did not affect the invasiveness, and that uPAR expression was
readily up-regulated by the tumour microenvironment both
in vivo in the tongue and ex vivo in the leiomyoma tissue.
Furthermore, we observed that cells with high uPAR expression
displayed increased gelatinolytic activity (figure 7 and 8).
Microenvironment induced uPAR expression
Analysis of the tongue- and skin tumours generated from cells
expressing low endogenous levels of uPAR, revealed that these
cells had up-regulated uPAR protein levels in vivo (EV1 and EV2
in figure 2). The IHC staining for uPAR was most prominent in
the periphery of these tumours (figure 2c), where the cells were in
contact with stromal cells including several types of immune cells.
Furthermore, cells invading the tissue of the leiomyoma also
showed enhanced uPAR expression (figure 5). These tumour
microenvironments are potential storage depots of cytokines,
chemokines and different growth factors such as transforming
growth factor b (TGFb), epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF) and vascular endothelial growth
factor (VEGF) [47–49], many of which have been shown to up-
regulate the expression of uPAR [43–46,50,51]. This could
explain why the expression is stronger along the tumour-stroma
interface, and in leiomyoma invading cells.
Specificity of the anti-uPAR antibody
The uPAR staining seen in the tumour cells was mostly located
intracellularly (figure 2), which prompted analysis of the specificity
of the anti-uPAR antibody used (file S1, figure S2). As the results
showed that the antibody is highly specific for uPAR, the apparent
lack of expected membrane staining could be explained by several
factors, where uPAR cleavage either partially (inter-domain
cleavage) or by complete shedding (cleavage of the GPI-anchor)
from the cell surface is one option [17]. Both phospholipase C and
D can cleave the GPI-anchor of uPAR [24,26], giving rise to
soluble uPAR (suPAR). The proportion of cell surface located
uPAR is also regulated by the rate of endocytosis. Both low-density
lipoprotein (LDL) receptor-related protein 1 (LRP1) and
Endo180/uPAR-associated protein (uPARAP) are involved in
turnover of uPAR. Although most uPAR is recycled back to the
cell surface, very active endocytosis could eventually deplete the
fraction of uPAR at the plasma membrane [52,53]. Thus, the
activity of both LRP1 and Endo180/uPARAP could very well
influence the cell surface levels of uPAR.
Soluble factors induce altered posttranslational
modifications of uPAR
To further investigate whether the soluble factors, such as
growth factors in the leiomyoma tissue were involved in the
regulation of uPAR expression, leiomyoma conditioned medium
was used to stimulate the cells (figure 6a). Soluble factors present
in the conditioned medium were able to override the shRNA in
the uPAR1 knock-down cells, and gradually increase the
expression of uPAR with time. Further experiments are needed
to identify the molecular mechanisms for this effect. Interestingly
Figure 5. Leiomyoma stroma is a strong inducer of uPAR expression. Representative images of low- (EV1-sh3) and high- (uPAR1-NT) uPAR-
expressing cells invading the ex vivo leiomyoma tissue. Cells were incubated for 7 and 14 days, as indicated. The tissue was IHC stained for uPAR.
Positive uPAR staining is seen as brown colour, counterstained with haematoxylin. Images were recorded at 10x magnification.
doi:10.1371/journal.pone.0105929.g005
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the conditioned medium induced a marked increase in the
molecular weight of uPAR when compared to control cells treated
with SFM. With five functional, and two potential, N-linked
glycosylation sites reported for murine uPAR [54], an alteration in
the glycosylation pattern could explain the increase in size. This is
interesting as modifications of the glycosylation pattern can
enhance uPAR’s ability to bind and activate uPA [55,56]. In
addition, more highly glycosylated variants of uPAR have been
observed in malignant thyroid tumour cells when compared to
normal thyroid cells [57]. Different cell types also express different
glycosylated variants of uPAR, and the glycosylation pattern can
be altered in response to different stimuli, such as PKC activation
as shown by PMA stimulation [58]. Ragno et al. [59] also reported
that the increased glycosylation of uPAR seen in the thyroid
tumour cells rendered uPAR less susceptible to cleavage by uPA,
plasmin and chymotrypsin. It has also been reported that
cleavage-resistant uPAR is less efficiently cleared from the cell
surface [60]. These are all events that could potentially increase
the pericellular proteolysis of the tumour cells. Deglycosylation of
the LCM treated and SFM treated cells revealed three distinct
bands (figure 6c, band no. 1–3), indicating that uPAR was cleaved.
Cells treated with LCM displayed more of uPAR D2+D3 (band
no. 2), but also to some extent showed more of full-length uPAR
(band no. 1). Thus, our finding that a large proportion of the
expressed uPAR is cleaved is not consistent with the hypothesis
that increased glycosylation protects uPAR against proteolytic
cleavage. However, this might be cell type specific since N-linked
glycans are known to be very heterogeneous in structure and that
Figure 6. Leiomyoma conditioned medium induced uPAR expression. Analysis of uPAR expression induced by the LCM or purified ECM
proteins in cultured uPAR knock-down cells. All Western blots were performed on whole cell lysates, and uPAR was detected using the polyclonal
anti-murine uPAR antibody (AF534). A: Cells were either cultured in LCM (LM) or serum free medium (SF) for 24 hours. Cells were harvested with
sample buffer and re-probing for b-actin was used as a loading control. B: uPAR1-NT cells were seeded on different ECM protein substrates,
incubated for 24 hours and harvested using RIPA buffer. 7.5 mg of total protein was loaded per lane. Equal loading was verified by re-probing for b-
actin. The poloxamer pluronic was used as a no-adhesion control. Col I = Collagen I, Vn= Vitronectin, Fn = Fibronectin, Lm= Laminin, ECL= Entactin,
Collagen, Laminin, and FBS = Foetal Bovine Serum. C: Cells cultured in LCM (LM) or serum free medium (SF) for 24 hours were harvested using sample
buffer and deglycosylated by PNGase F treatment (+) as indicated. Re-probing for b-actin was used as a loading control. The three bands detected by
the anti-uPAR antibody are labelled 1, 2, and 3, respectively.
doi:10.1371/journal.pone.0105929.g006
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many proteins exist in various glycoforms in different diseases [61].
Thus, it is therefore still uncertain whether the shift in the
molecular weight of uPAR that we observed was due to a change
in glycosylation, or whether it is due to increased levels of full
length uPAR.
High uPAR levels increases the activity of gelatinolytic
enzymes
A stromal-induced alteration in expression levels, glycosylation
and/or cleavage of uPAR could potentially affect the pericellular
proteolysis of tumour cells. Cleavage between D1 and D2 of uPAR
renders it unable to bind pro-uPA, and may therefore represent a
natural regulatory mechanism to avoid overactive proteolysis [7].
It might also reflect a highly active PA system, as uPA and plasmin
can both cleave uPAR [14]. Whether the expressed uPAR in the
tumours or the cells invading the leiomyoma tissue display altered
glycosylation and/or cleavage has not been investigated. However,
the results obtained using the LCM suggests that such modifica-
tions are plausible. When tongue tumours were examined for
gelatinolytic activity, tumours expressing high levels of uPAR
displayed a substantial ability to activate gelatinolytic enzymes
compared to tumours with low uPAR levels (figure 7). Similar
results were obtained when the cells invading the leiomyoma tissue
were examined (figure 8). Cells invading deep into the tissue had
up-regulated uPAR levels and displayed an increased ability to
degrade gelatin, hence activate gelatinolytic enzymes. EDTA-
treatment of leiomyoma tissue sections indicated that the activity
seen in the invading cells mainly originates from non-metallopro-
teinases such as uPA and plasmin, underscoring a role for uPAR
and the stroma in the regulation of gelatinolytic activity. On the
other hand other enzymes such as trypsin and cathepsins could
also cause the gelatin degradation seen in the tumours and the
Figure 7. Gelatinolytic activity is enhanced in tumours expressing high levels of uPAR. ZBF-fixed tongue tumours were sectioned and
analysed for the presence of gelatinolytic activity using DQ-gelatin in situ zymography. Gelatinolytic activity is seen as green fluorescence. A:
Representative confocal images of tongue tumours generated from the uPAR1-NT cells (left panel) and EV1-sh3 cells (right panel). B: Quantification of
fluorescence intensity (analysed using Volocity as described in materials and methods) for a minimum of 5 images per tumour, presented as mean
values. Three individual uPAR1-NT tumours (No.1–No.3) and three EV1-sh tumours (No.1–No.3) were analysed. Error bars shows the standard
deviation (+SD) between the five images analysed. Dark grey bars represents gelatinolytic activity in the tumour sections, light grey bars represents
gelatinolytic activity in tumour sections treated with the metalloproteinase inhibitor EDTA. Mann-Whitney rank sum test; ***p,0.001, **p,0.01, *p,
0.05.
doi:10.1371/journal.pone.0105929.g007
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invading cells, and further investigations are needed in order to
reveal the identity of the proteolytic enzymes involved. Tumours
expressing either high- or low levels of uPAR displayed similar
growth patterns with few signs of aggressive behaviour. This
indicates that the expression of uPAR and subsequent activation of
gelatinolytic enzymes is not sufficient to induce infiltrative growth
and metastatic behaviour of the AT84 cells in this in vivo tumour
model. Several in vitro studies have suggested that suPAR could
function as an inhibitor for tumour progression, scavenging the
active uPA [62,63]. Whether this is the case in our tumour model
is an interesting possibility. Thus, further studies on the role of
uPAR cleavage and glycosylation in relation to tumour invasion
and metastasis formation are warranted.
Conclusions
Taken together, we have observed that the tumour microen-
vironment is involved in the induction of uPAR expression.
Furthermore the increased expression of uPAR, either by
overexpression or by natural up-regulation, increased the activity
of gelatinolytic enzymes in these cells, however this did not affect
the tumour invasiveness in our mouse model. Further studies on
the observed effects of the tumour microenvironment on
expression and post-translational modifications of uPAR are
warranted. Unravelling the biological significance of posttransla-
tional modifications of uPAR, as well as the mechanisms
regulating them, might provide answers to why uPAR is often
associated with poor prognosis in many types of cancers.
Methods
Ethical statement
The experimental protocol was approved by the competent
local authority reporting to the Norwegian National Animal
Research Authority, project licence no. FOTS 2598 and 4020/
date of approval 27.04.2010 and 31.01.2012, respectively. All
animal procedures were carried out in accordance with the
Norwegian Regulations on Animal Experimentation (REG 1996-
Figure 8. Gelatinolytic activity is enhanced in cells invading leiomyoma tissue. ZBF-fixed leiomyoma tissue was sectioned and analysed for
the presence of gelatinolytic activity using DQ-gelatin in situ zymography. Gelatinolytic activity is seen as green fluorescence, nuclei are stained blue
with DAPI. Representative confocal images of cells expressing either low- (EV1-sh3, left panels) or high (uPAR1-NT, right panels) levels of uPAR
invading the ex vivo leiomyoma tissue. The upper panels show gelatinolytic activity in the tissue, while the lower panels show tissue sections treated
with the metalloproteinase inhibitor EDTA.
doi:10.1371/journal.pone.0105929.g008
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01-15 no. 23) and in agreement with European Convention for the
Protection of Vertebrate Animals used for Experimental and
Other Scientific Purposes (Convention No. 123 Issued by the
Council of Europe) [64]. Experimental applications included
experimental set-up, rationale for the experiment, and efforts
made to refine, replace and reduce the animal experiments. The
work is reported according to the ARRIVE guidelines [65]. Use of
patient material (leiomyoma tissue) was approved by the Northern
Ostrobothnia Hospital District Ethics Committee (statement #8/
2006 and amendment 19/10/2006), with written informed
consent from the donors [66].
Cell culture
The mouse tongue SCC cell line AT84, originally isolated from
a C3H mouse [41], was kindly provided by Professor Shillitoe,
Upstate Medical University, Syracuse, NY [67]. AT84 has
previously been reported as invasive and metastatic when injected
into the floor of the mouth through an extra-oral route [67]. Cells
were cultured at 37uC, 5% CO2 in a humid environment in
NaHCO3-buffered RPMI-1640 (R8758, Sigma Aldrich, St. Louis,
USA) supplemented with 10% FBS (F7524, Sigma Aldrich, St.
Louis, USA). For AT84 cells overexpressing uPAR, the culture
medium was supplemented with 5 mg/ml puromycin dihydro-
chloride (P9620, Sigma Aldrich, St. Louis, USA). uPAR shRNA
knock-down cells were cultured in RPMI-1640 supplemented with
10% FBS, 5 mg/ml puromycin dihydrochloride (Sigma Aldrich,
St. Louis, USA) and 300 mg/ml G418 (G8168, Sigma Aldrich, St.
Louis, USA). Cells were also routinely checked for mycoplasma
infections.
Cloning and overexpression of mouse Plaur
The mouse gene for uPAR, Plaur, was cloned using the
Gateway cloning system (Invitrogen, CA, USA). RNA from mouse
J774 macrophage cells was used as template and AttB-kozac-
uPARmouse Fw primers (GGGGACAAGTTTGTA-
CAAAAAAGCAGGCTTCGCCACCATGGGT-
CACCCGCCGCTGCTGCCG) and AttB-uPAR-mouse Rev
primers (GGGGACCACTTTGTACAAGAAAGCTGGGTT-
TAGGTCCAGAGGAGAGTGCCTCCCCA) were used to make
the Gateway attB-PCR product. Entry clones (pENTR/kozac/
uPARmouse) were created by cloning the attB-PCR product into
the pDONR-221 vector by BP clonase. The destination vector
pcDNA5/FRT/TO (Invitrogen, Paisley, UK) was modified by
replacing the FRT-site and the neomycin cassette with reading
frame A (RfA) (Invitrogen, Paisley, UK) and the puromycin
resistance gene controlled by the PGK promoter from the
pLKO.1 vector (Thermo Scientific, Wilmington, USA), and
termed pDest/TO/PGK-puro. The uPAR PCR-product was
transferred to the destination vector by LR clonase and named
pDest/TO/PGK-puro/uPAR. The pDest/TO/PGK-puro/
uPAR, and pDest/TO/PGK-puro as control, were linearized by
ScaI restriction enzyme digestion and transfected into AT84 cells
using Lipofectamine LTX & Plus reagent (Invitrogen, Carlsbad,
USA). Successfully transfected cells were selected in culture
medium supplemented with 5 mg/ml puromycin dihydrochloride
(Sigma Aldrich, St. Louis, USA), and single cell clones were
expanded for further work. Two clones expressing high levels of
uPAR were selected and named uPAR1 and uPAR2, and two
clones containing only the empty vector and hence expressing low
levels of uPAR were selected and named EV1 and EV2.
shRNA knock down of mouse Plaur
Constitutive knock-down of Plaur was achieved using MIS-
SION shRNA Plasmid DNA (NM_011113, Sigma Aldrich, St.
Louis, USA). Five different shRNA constructs TRCN0000088818
(construct 1), TRCN0000294900 (construct 2),
TRCN0000294902 (construct 3), TRCN0000362694 (construct
4) and TRCN0000362760 (construct 5) under the control of the
U6 promoter of the pLKO.1-neo vector were purchased from
Sigma Aldrich (St. Louis, MO, USA). An empty pLKO.1-neo
vector (EV) and a pLKO.1 vector containing non-target shRNA
(NT) were used as controls. The constructs were stably transfected
into uPAR1 and EV1 single cell clones using Lipofectamine 2000
(Cat# 11668-019, Invitrogen, Carlsbad, USA). Successfully
transfected cells were selected in culture media supplemented
with 5 mg/ml puromycin dihydrochloride and 1 mg/ml G418,
and single cell clones were expanded for further work. The
selected clones were given names as listed in the flow chart in
figure 3b.
Antibodies
Antigen affinity-purified polyclonal goat anti-mouse uPAR
antibody (AF534) was from R&D Systems (Minneapolis, MN,
USA) and used at 1:100 in flow cytometer analysis, 1:200 in
immunohistochemistry (IHC) for 1 hour at room temperature, and
1:1000 in Western blotting. For flow cytometery, the Alexa Fluor
488 donkey anti-goat antibody (A11055) from Invitrogen (Carls-
bad, USA) was used at 1:500. For Western blotting, HRP-
conjugated anti-goat/sheep (A9452) was used at 1:100.000, and
HRP-conjugated anti-b-actin (A3854) at 1:25000 (Sigma Aldrich,
St. Louis, USA).
Western blotting
Cells were detached using trypsin (0.25% in PBS with 0.05%
Na2EDTA), counted and seeded according to the specific assay.
Untreated cells were seeded in serum-containing medium and
incubated for 24 hours. For the ECM protein assay, plates were
coated for 1 hour at 37uC with either Pluronic F108NF Prill
Poloxamer 338 (BASF Corporation, Florham Park, NJ, USA) and
fibronectin which was a kind gift from Professor Staffan Johansson,
Uppsala University Sweden, collagen I (#C3867-1VL, Sigma
Aldrich, St. Louis, MO, USA), vitronectin was purified from
human blood as previously described [68], laminin (Lm) (#08–
125, Upstate, Lake Placid, NY, USA), entactin, collagen and
laminin (ECL) cell attachment matrix (#08–110, Upstate, Lake
Placid, NY, USA), 10% FBS in RPMI-1640 medium, 1:5 dilution
of Matrigel (#BS6234) and growth factor reduced (GFR) Matrigel
(#BS354230) (BD Biosciences, Bedford, MA, USA). Cells were
seeded in serum-free RPMI-1640 medium (SFM) and incubated
for 24 hours. For the urokinase inhibitor experiment, cells were
seeded in serum-containing medium and incubated for 24 hours.
Media was replaced with fresh serum-containing medium with
either 10 mM, 20 mM or 30 mM BC11 hydrobromide (#4372,
Trocris Bioscience, Ellisville, MO, USA), or no added inhibitor as
a control. Cells were incubated for 72 hours and fresh medium
containing inhibitor was added every 24 hours. For the LCM-
experiment, cells were seeded in serum containing medium. After
24 hours the medium was exchanged either for SFM or
conditioned medium (see ‘‘organotypic invasion model’’). Cell
lysates were prepared by removing the culture medium and
adding either RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM
NaCl, 1% Triton, 1% sodium dexycholate, 0.1% SDS) with added
1x SIGMAFAST Protease inhibitor (S8830, Sigma Aldrich,
St.Louis, MO, USA), or samples buffer (0.05 M Tris-HCl
pH 6.8, 2% SDS, 10% glycerol, 0.1% bromphenol blue) and
cells were harvested by scraping. Cells harvested with RIPA buffer
were added 1x samples buffer. All cell lysates were sonicated and
boiled before the samples were loaded onto NuPAGE Novex 4%–
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12% Bis-Tris gels (Invitrogen, Eugene, USA), and subjected to
reducing (PNGase F treated cells) or non-reducing SDS-PAGE.
Recombinant mouse soluble His-tagged uPAR was loaded as a
positive control in some experiments (CSI20008, Cell Sciences,
Canton, MA, USA). Proteins were blotted onto PVDF membranes
(Millipore Corp., Bedford, MA, USA). Blocking was done with 5%
non-fat dry milk in Tris-buffered saline (150 mM NaCl, 20 mM
Tris, pH 7.4) supplemented with 0.1% Tween 20. Membranes
were incubated with primary antibody recognizing mouse uPAR
(AF534). For some experiments the total protein concentration
was measured using the Direct Detect Spectrometer (Millipore
corp., Bedford, MA, USA), and equal protein amounts were
loaded per lane. For all experiments, equal loading was controlled
by re-probing for b-actin (A3854). Western blotting Luminol
Reagent (Santa Cruz Biotechnology Inc., USA) was used for
antibody detection, and images were obtained using the Fujifilm
LAS-4000 imaging system (Fujifilm, Tokyo, Japan).
Isolation of cell membrane fractions
Cells were harvested using 10 ml ice cold 16PBS by scraping
and spun at 20216g for 10 minutes. The pellet was re-suspended
in 3 ml buffer A (50 mM Tris-HCl, pH 8.0, 5 mM CaCl2,
containing 1x SIGMAFAST Protease Inhibitor cocktail (S8830-
20TAB, Sigma Aldrich, St. Louis, USA) and 10 mM EDTA). The
cell suspension was then homogenized using a Dounce homoge-
nizer, ultra-centrifuged at 50 0006g for 1 hour at 4uC. The pellet
was re-suspended in 1.5 ml buffer B (20 mM Tris-HCl, pH 7.4,
8.7% sucrose containing 1x SIGMAFAST and 10 mM EDTA).
The suspension was loaded atop a 37.5% sucrose solution and
ultra-centrifuged at 100 0006g for 1 hour 4uC. The interface layer
was collected and added to 8 ml of buffer B. The suspension was
ultra-centrifuged at 100 0006g for 1 hour 4uC, and the pellet
containing the cell membrane fraction, was re-suspended in 100 ml
buffer A. The total protein concentration was determined using
the DC Protein Assay (Bio-Rad Laboratories, Hercules, USA), and
a total of 53.3 mg protein was loaded per lane and analysed by
Western blotting as described above.
Flow cytometery
Cultured cells were detached with 1 mM EDTA and washed
once in RPMI-1640 w/10% FBS. All subsequent washing steps
were performed with Opti-MEM (#31985-047, Gibco, Paisley,
UK) containing 1% BSA, and blocking was done with Opti-MEM
w/5% BSA. Non-permeablized cells were labelled using anti-
mouse uPAR antibody (AF534) and Alexa Fluor 488 donkey anti-
goat secondary antibody (A11055). Cells were subsequently
analysed using a BD FACSAria (BD Biosciences, San Jose, USA).
Reverse transcriptase quantitative PCR (RT-qPCR)
Cells cultured in SFM (1.716105 cells) for 24 hours were
harvested using RTL buffer (Qiagen, Hilden, Germany) contain-
ing 75 mM dithiothreitol (DTT) (Sigma Aldrich, St. Louis, USA).
Samples were homogenized using the QIAshredder kit (Qiagen,
Hilden, Germany) followed by total RNA extraction using the
RNeasy kit (Qiagen, Hilden, Germany). Quantity and purity of
the extracted RNA was determined using the NanoDrop
spectrophotometer (Thermo Scientific, Wilmington, DE, USA),
and RNA integrity was assessed using the Experion automated
electrophoresis system (Bio-Rad Laboratories, Hercules, USA).
mRNA expression levels were analysed using reverse transcription
quantitative PCR (RT-qPCR) on a Stratagene Mx3000P instru-
ment (Stratagene, La Jolla, USA). cDNA was synthesized from
1 mg total RNA using the QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany). Target cDNA, corresponding to
10 ng RNA, was amplified through 40 cycles in a 25 ml qPCR mix
(RT2 SYBR Green/ROX, SA Biosciences, USA) containing 1 ml
Qiagen primer mix (uPAR: QT00102984, uPA: QT00103159,
Plasminogen: QT01053332, b-actin: QT00095242, and TRFC:
QT00122745). A dissociation curve was routinely run at the end of
every PCR to verify sample purity, primer specificity and absence
of primer dimers. qPCR cycling conditions: Step 1: 95uC for
10 min. Step 2: 95uC for 30 sec, 55uC for 1 min and 72uC for
30 sec was repeated 40 times. Step 3 (dissociation curve): 95uC for
1 min, 55uC for 30 sec and 95uC for 30 sec. Absence of genomic
DNA and contaminants was confirmed by performing no reverse
transcriptase (NoRT) controls with every round of RNA purifica-
tion, and non-template controls (NTC) on each primer set,
respectively. For each experiment RNA was purified from at least
three biological replicates (N$3). Reverse transcription was
performed on all biological replicates, and each biological replicate
was loaded as two technical replicates per RT-qPCR run. When
needed, an inter-plate calibrator was used to enable comparisons
of different runs. The delta-delta Cq method [69] was used to
determine the relative amount of target mRNA in samples
normalized against the average expression of the two reference
genes Trfc and b-actin. The numbers are presented as fold
differences where the lowest value is set to 1.
Gelatin and plasminogen zymography
Cells were seeded in 96-well plates at 30.000 cells per well. They
were incubated overnight and washed three times in PBS before
the medium was exchanged for SFM. The medium was harvested
after 24 hours and spun down to remove any cells. uPA levels were
assessed by gelatin and combined gelatin-plasminogen zymogra-
phy respectively, as previously described [70]. When analysing
plasminogen activators, a final concentration of 10 mg/ml of
plasminogen (#528175, Merck KGaA, Darmstadt, Germany) was
added to the gel. As controls, purified mouse HMW-uPA (Mr
44 kDa) (MUPA), mouse plasmin (MPLM) (Molecular Innova-
tions, Peary Court, Novi, USA) and a mixture of human
proMMP-9 monomer (Mr 92 kDa) and human proMMP-2 (Mr
72 kDa) were used.
Syngeneic mouse model for OSCC tumours
From a pilot study, 10 000 cells were found to be sufficient to
produce tumours in both tongue and skin and were therefore
chosen for the subsequent experiments, and all efforts were made
to minimize suffering. To enable a realistic study of uPAR
expressing tumours, compatible with host expression of plasmin-
ogen activators, the immune competent mouse strain C3H/
HeNHsd (Harlan, Netherlands) was chosen for this study. Cells
were detached from culture flasks using trypsin, washed once in
serum containing media, and twice in PBS. Cells were re-
suspended in 0.9% NaCl to a final concentration of 46105 cells/
ml and 25 ml of cell suspension containing 10 000 cells was
injected into the anterior part of the tongue or subcutaneously into
the flank of six week old female mice (mean 20 g). Mice were
anaesthetized with 100–150 ml of hypnorm (Vetapharma, Leeds,
UK)/dormicum (B. Braun Medical A/S, Oslo, Norway) depend-
ing on bodyweight. A total of 80 mice were used; EV1 and EV2
groups (10 mice per group), uPAR1 and uPAR2 groups (10 mice
per group), EV1-sh group (16 mice), uPAR1-NT (8 mice), uPAR1-
sh group (16 mice). The control group consisted of 5 mice of which
4 received saline injections, and one received no injection. Mice
were euthanized using CO2 to enable recovery of proximal lymph
nodes, at the endpoint of 14 days, or earlier if more than 10% of
the body weight was lost during the experimental period. Tongues,
liver, lungs as well as proximal and distal lymph nodes were
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harvested from the mice. In the pilot study, the mandible was
analysed for metastasis as this had been reported previously [67],
but since no metastases were found here, they were not analysed in
subsequent experiments. Lungs, liver and mandibles were fixed
using 4% neutral buffered formalin (NBF), while tongues and
lymph nodes were fixed using a zinc-based fixative (ZBF)
(36.7 mM ZnCl2, 27.3 mM ZnAc262H2O and 0.63 mM CaAc2
in 0.1 mol/L Tris pH 7.4). Lymph nodes were paraffin embedded,
sectioned and hematoxylin & eosin (H/E) stained to screen for
metastasis. Lungs and livers were sliced and examined under a
dissecting microscope. The invasive growth of the tumour was
assessed by a pathologist via microscopic evaluation of H/E
stained sections.
Organotypic invasion assay
Leiomyoma discs were prepared as previously described [39].
The discs were subsequently freeze-dried and stored at 4uC until
use. All experiments were performed on discs originating from the
same leiomyoma. Before use, four leiomyoma discs were placed in
20 ml SFM, and rehydrated overnight at 4uC on rotation. This
medium was sterile filtered and kept for further experiments,
termed ‘‘leiomyoma conditioned-medium’’ (LCM). A total of
0.46106 cells suspended in 50 ml SFM were seeded on top of the
discs, and three discs were used per cell line (N = 3). Cells were
allowed to attach and invade the tissue over a 7 or 14 day period,
using 10% FBS containing medium as attractant. Discs were then
fixed in ZBF, dehydrated and paraffin-embedded. Discs where
HSC-3 cells had been added were used as positive controls for
invasion, as these are known to invade the leiomyoma tissue [39].
Tissue section of the leiomyoma discs were analysed by
immunohistochemistry (IHC). Sections of leiomyoma tissue
without added cells were used as negative controls. Images were
recorded using the Leica DCF425 camera (Leica Microsystems,
Heerburg, Switzerland) and the Leica Application Suite (LAS
version 3.7.0, Leica Microsystems, Heerburg, Switzerland).
Immunohistochemistry (IHC)
For analysis of uPAR expression the ZBF fixed leiomyoma discs
and mouse tongue- and skin tumours were IHC stained as
previously described [70]. The primary antibody was diluted in
5% BSA in PBS. For visualization of the uPAR primary antibody,
the Polink-2 Plus HRP Detection kit for goat primary antibody
from GBI Labs (GBI Labs, Mukilteo, USA) was used. The
chromogen diaminobenzidine (DAB) was used to visualize the
secondary HRP-linked antibody. Sections in which the primary
antibody was replaced with 5% BSA were used as negative
controls and showed no staining. The specificity of the anti-uPAR
antibody was verified by pre-absorbing the antibody with
recombinant histidine-tagged mouse uPAR (His-uPAR) (see file
S1 and figure S2). Tumour sections were scored for uPAR
expression, where staining intensity of the tumour cells was set as
follows: non-existent (0), weak (1), moderate (2) and strong (3). The
score for number of positive cells was set as follows: 0% (0), less
than 10% (1), 10–50% (2) and more than 50% (3). The two
variables were multiplied giving the final staining index (SI).
In situ zymography
The gelatinolytic activity in the tongue tumours established
from the different uPAR expressing clones, and the different
uPAR expressing clones invading the leiomyoma tissue for 7 days
were assessed by in situ zymography. Four mm sections of ZBF-
fixed and paraffin embedded tumours were analysed as previously
described [70]. The contribution of enzymatic activity from
gelatinolytic enzymes that were not metal dependent was assessed
by incubating the sections in 20 mM of EDTA (a metalloprotei-
nase inhibitor). Auto-fluorescence was assessed by incubating the
sections at 220uC for 2 hours immediately after the substrate was
added. Images were recorded using a Leica TSC SPS confocal
laser microscope and the Leica Application Suite Advanced
Fluorescence software (Leica, Wetzlar, Germany). Confocal
images were analysed using the Volocity software (Improvision,
PerkinElmer Inc., Waltham, USA). A minimum of 5 images were
analysed per section, where a standard protocol was made and
used for all images. To avoid background signalling from the
fluorescing epithelia, images containing epithelia were cropped so
that only tumour cells were analysed. The lower cut-off for
intensity was set at 100 and the upper cut-off at 255. The
minimum object size was set to 21 mm2. Read out numbers of
mean intensity of the objects and sum of the area (mm2) were
collected. These numbers were multiplied and are presented in
graphs as averages per section.
Deglycosylation by PNGase F treatment
Lysates of cells treated with either LCM or SFM for 24 hours
was treated with PNGase F (P0704S, New England BioLabs,
Beverly, MA, USA) to remove all N-linked glycosylations. The
procedure was performed according to the manufacturer’s
protocol. In brief, 10 ml of cell lysate (see ‘‘Western blotting’’
and LCM-treatment) were added 1x denaturing buffer and boiled
for 10 minutes. 1x G7 reaction buffer, 1% NP40 and 0.5 ml
PNGase F were added in a total volume of 20 ml and incubated for
1 hour at 37uC. Samples were then analysed by SDS-PAGE and
either Western blotting or mass spectrometry.
Statistical analysis
Data are presented as mean values + standard error of mean (+
SEM) or + standard deviation (+SD), specified in the figure legend.
The differences between groups were assessed by one-way analysis
of variance (ANOVA), followed by Tukey’s multiple comparisons
post-test. In some cases Mann-Whitney rank sum test was
performed, indicated in the figure legend. P-values,0.05 were
accepted as statistically significant. Graphics were made using
Excel, and statistical analysis were performed using SPSS Statistics
19 for Windows or SigmaPlot (SPSS Corp., Chicago, Il, USA).
Independent replicates (N) for the different data are presented in
the figure legends.
Mass spectrometry
Gel pieces were subjected to in gel reduction, alkylation, and
tryptic digestion using 6 ng/ml trypsin (V511A, Promega,
Wisconsin, USA) [71]. OMIX C18 tips (Varian, Inc., Palo Alto,
CA, USA) was used for sample clean-up and concentration.
Peptide mixtures containing 0.1% formic acid were loaded onto a
Thermo Fisher Scientific EASY-nLC1000 system and EASY-
Spray column (C18, 2 mm, 100 A˚, 50 mm, 15 cm). Peptides were
fractionated using a 2–100% acetonitrile gradient in 0.1% formic
acid over 50 min at a flow rate of 250 nl/min. The separated
peptides was analysed using a Thermo Scientific Q-Exactive mass
spectrometer. Data was collected in data dependent mode using a
Top10 method. The raw data was processed using the Proteome
Discoverer 1.4 software. The fragmentation spectra were searched
against the Swissprot SwissProt_2011_12 database using an in-
house Mascot server (Matrix Sciences, UK). Peptide mass
tolerances used in the search were 10 ppm, and fragment mass
tolerance was 0.02 Da. Peptide ions were filtered using a false
discovery rate (FDR) set to 2% for peptide identifications.
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Supporting Information
Figure S1 Full gel images of gelatin- and plasminogen-
gelatin zymography. Full version of the cropped images
presented in figure 1f. PlgZym = plasminogen gelatin zymogra-
phy, GelZym = gelatin zymography, mPLM = mouse plasmin,
std = standard containing human proMMP-9 and human
proMMP-2.
(TIF)
Figure S2 Specificity of the anti-uPAR antibody (AF534).
The polyclonal anti-murine uPAR antibody was preabsorbed with
recombinant His-tagged mouse uPAR (His-uPAR) before IHC.
The antibody-His-uPAR-complexes were removed by precipita-
tion and serial sections of mouse skin tumour tissue expressing high
levels of uPAR (uPAR1) were stained. IHC staining with A)
untreated antibody, B) antibody pre-absorbed without His-uPAR,
C) antibody pre-absorbed with His-uPAR. Sections were coun-
terstained with haematoxylin. Images were recorded at 20x
magnification.
(TIF)
Figure S3 Tumour microenvironment induced uPAR
protein expression in skin tumours. Tumour growth
pattern and uPAR protein levels in skin tumours generated from
the EV1, EV2, uPAR1 and uPAR2 cells. A–B: Representative
images depicting the tumour growth pattern at the tumour-stroma
interface in hematoxylin/eosin stained EV1 (A) and uPAR1 (B)
tumours. Images were recorded at 10x magnification. C–D:
Representative images depicting the IHC uPAR staining of the
EV1 (C) or uPAR1 tumours (D). Images were recorded at 4x
magnification. E–H: The images show high power magnification
(20x magnifications) of the EV1 (E), uPAR1 (F), EV2 (G) and
uPAR2 (H) tumours IHC stained for uPAR. Positive uPAR
staining is seen as brown colour, and counterstaining was done
with haematoxylin. I: The average staining index (SI) of the uPAR
staining in the tumours. Maximum obtainable score is 9. The error
bars shows the +SEM. EV1, N = 9; EV2, N = 10; uPAR1, N = 8;
uPAR2, N = 4. One-way ANOVA; **p,0.01, *p,0.05. T = Tu-
mours, S = Stroma.
(TIF)
Figure S4 Knock-down of Plaur. shRNA knock down of
uPAR in uPAR1 cells. A: Western blot analysis of whole cell
lysates from uPAR1 cells transiently transfected with five different
shRNA constructs. The positive control (pos. ctrl) is non-
transfected uPAR1 cells. B: Western blot analysis of whole cell
lysates from uPAR1 bulk transfected (mixed clones) cells. Cells
were transfected with shRNA construct 3, 4 and 5, empty vector
or non-target shRNA. A–B: Cells were harvested with sample
buffer and analysed by Western blotting using the polyclonal anti-
murine uPAR antibody (AF534). Equal loading was controlled by
re-probing for b-actin.
(TIF)
Figure S5 Quantification of leiomyoma invasion. Cells
invading the leiomyoma tissue were recorded for three individual
discs per cell line and one invasion ‘‘hot spot’’ was counted per
disc. The average value is presented, and error bars show the
standard error of mean (+SEM).
(TIF)
Figure S6 Leiomyoma conditioned medium induced
uPAR expression. Cells were cultured in LCM (LM) or serum
free medium (SF) for 48 hours. All Western blots were performed
on whole cell lysates, and uPAR was detected using the polyclonal
anti-murine uPAR antibody (AF534). Re-probing for b-actin was
used as a loading control.
(TIF)
Figure S7 Inhibition of uPA hinders cleavage of uPAR
expressed by AT84 cells. A: Cultured cells were treated with
increasing concentrations of the uPA inhibitor BC11 hydrobro-
mide for 72 hours. As a control, cells were cultured without the
inhibitor. Cells were harvested using RIPA buffer and total protein
was measured in whole cell lysates. A total protein amount equal
to 10 mg was either deglycosylated by PNGase F treatment (+), or
received the same treatment without addition of PNGase F (2).
uPAR was detected using the polyclonal anti-murine uPAR
antibody (AF534), and equal loading was verified by re-probing for
b-actin. B: Different combinations of HMW-uPA (uPA), plasmin
(Plm), plasminogen (Plg) and BC11 hydrobromide (BC11) were
mixed and incubated for 1 hour at room temperature. The activity
of the proteins was subsequently assessed using either gelatin-
plasminogen zymography (top panel) or gelatin zymography
(lower panel). Lane 1: Standard (std) containing human
proMMP-9 and human proMMP-2. Lane 2: Not in use. Lane 3:
HMW-uPA. Lane 4: Plasminogen. Lane 5: Plasmin. Lane 6: BC11
hydrobromide. Lane 7: Plasmin and BC11 hydrobromide. Lane 8:
HMW-uPA and BC11 hydrobromide. Lane 9: HMW-uPA and
plasminogen. Lane 10: HMW-uPA, plasminogen and BC11
hydrobromide. Lane 11: Not in use. Lane 12: Standard containing
human proMMP-9 and human proMMP-2. Arrow indicates the
position of active plasmin.
(TIF)
Figure S8 Quantified gelatinolytic activity in tongue
tumours. ZBF-fixed uPAR1 and EV1 tongue tumours were
sectioned and analysed for the presence of gelatinolytic activity
using DQ-gelatin in situ zymography. The quantification of
fluorescence intensity (analysed using Volocity as described in
materials and methods) for a minimum of 5 images per tumour is
presented as mean values. A total of three tumours per cell line
were analysed. Each bar represents the mean fluorescence values
from each of the three individual tumours (no.1- no.3). The error
bars show the standard deviation (+SD) between the five images
analysed for each tumour. Mann-Whitney rank sum test; ***p,
0.001, **p,0.01, *p,0.05.
(TIF)
File S1 Specificity of the anti-uPAR antibody (AF534).
(DOCX)
File S2 Less efficient knock-down of Plaur in bulk
transfected cells.
(DOCX)
File S3 Quantification of leiomyoma invasion.
(DOCX)
File S4 Inhibition of uPA hinders cleavage of uPAR
expressed by AT84.
(DOCX)
Acknowledgments
The authors are indebted to Professor Edward Shillitoe, Upstate Medical
University, NY, USA for kindly providing the AT84 cell line. The authors
thank Cristiane Cavalcanti Jacobsen, Eli Berg, Bente Mortensen and Marit
Nilsen for excellent technical assistance, Peter McCourt for linguistic
revision of the manuscript, Roy Lysa˚ at the Imaging core facility (UiT –
The Arctic University of Norway) for technical assistance with FACS
analysis, Jack-Ansgar Bruun and Toril Anne Grønset at the Proteomic core
facility (UiT – The Arctic University of Norway) for the mass spectrometry
Stromal Induced uPAR Expression
PLOS ONE | www.plosone.org 14 August 2014 | Volume 9 | Issue 8 | e105929
analysis, and Siri Knutsen at the Unit of Comparative Medicine for
guidance and assistance with the animal experiments.
Author Contributions
Conceived and designed the experiments: SM EHO JOW LUH GS.
Performed the experiments: SM EHO NL EP SES RH. Analyzed the data:
SM EHO NL EP SES RH TS JOW LUH GS. Contributed reagents/
materials/analysis tools: SM EHO NL EP SES RH TS JOW GS.
Contributed to the writing of the manuscript: SM EHO NL EP SES RH
TS JOW LUH GS.
References
1. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, et al. (2002)
Presentation, treatment, and outcome of oral cavity cancer: a National Cancer
Data Base report. Head Neck 24: 165–180.
2. Rothenberg SM, Ellisen LW (2012) The molecular pathogenesis of head and
neck squamous cell carcinoma. J Clin Invest 122: 1951–1957.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
4. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA
Cancer J Clin 62: 10–29.
5. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation
system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25–40.
6. Duffy MJ (2004) The urokinase plasminogen activator system: role in
malignancy. Curr Pharm Des 10: 39–49.
7. Blasi F, Sidenius N (2010) The urokinase receptor: focused cell surface
proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923–1930.
8. Zhang Z, Pan J, Li L, Wang Z, Xiao W, et al. (2011) Survey of risk factors
contributed to lymphatic metastasis in patients with oral tongue cancer by
immunohistochemistry. J Oral Pathol Med 40: 127–134.
9. Schmidt M, Hoppe F (1999) Increased levels of urokinase receptor in plasma of
head and neck squamous cell carcinoma patients. Acta Otolaryngol 119: 949–
953.
10. Magnussen S, Rikardsen O, Hadler-Olsen E, Uhlin-Hansen L, Steigen SE, et al.
(2014) Urokinase plasminogen activator receptor (uPAR) and plasminogen
activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage
oral squamous cell carcinomas (OSCC) PLoS One In Press.
11. Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev
Mol Cell Biol 11: 23–36.
12. Svineng G, Magnussen S, Hadler-Olsen E (2012) Plasmin and the plasminogen
activator system in health and disease. In: Karamanos NK, editor. Extracellular
Matrix: Pathobiology and Signaling. Germany: Walter de Gruyter GmbH & Co.
261–290.
13. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev
Mol Cell Biol 3: 932–943.
14. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, et al. (1992)
Urokinase plasminogen activator cleaves its cell surface receptor releasing the
ligand-binding domain. J Biol Chem 267: 18224–18229.
15. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, et al. (2002)
Metalloproteases cleave the urokinase-type plasminogen activator receptor in the
D1–D2 linker region and expose epitopes not present in the intact soluble
receptor. Thromb Haemost 88: 298–306.
16. Hoyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, et al. (2001) Urokinase-
catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Biochem J 358: 673–679.
17. Montuori N, Visconte V, Rossi G, Ragno P (2005) Soluble and cleaved forms of
the urokinase-receptor: degradation products or active molecules? Thromb
Haemost 93: 192–198.
18. Behrendt N, Ronne E, Dano K (1996) Domain interplay in the urokinase
receptor. Requirement for the third domain in high affinity ligand binding and
demonstration of ligand contact sites in distinct receptor domains. J Biol Chem
271: 22885–22894.
19. Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K (1997) Cell-surface
acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 243: 21–
26.
20. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, et al. (1997) A
urokinase-sensitive region of the human urokinase receptor is responsible for its
chemotactic activity. EMBO J 16: 7279–7286.
21. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, et al. (2002) The
fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic
receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 99: 1359–1364.
22. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P (2002) The cleavage of
the urokinase receptor regulates its multiple functions. J Biol Chem 277: 46932–
46939.
23. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, et al. (2004)
Urokinase induces basophil chemotaxis through a urokinase receptor epitope
that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
J Immunol 173: 5739–5748.
24. Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, et al. (1999) Cellular
glycosylphosphatidylinositol-specific phospholipase D regulates urokinase recep-
tor shedding and cell surface expression. J Cell Physiol 180: 225–235.
25. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, et al. (2004)
Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by
neutrophil elastase and cathepsin G. J Immunol 172: 540–549.
26. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, et al. (1991) Cellular
receptor for urokinase plasminogen activator. Carboxyl-terminal processing and
membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266: 1926–
1933.
27. Solberg H, Romer J, Brunner N, Holm A, Sidenius N, et al. (1994) A cleaved
form of the receptor for urokinase-type plasminogen activator in invasive
transplanted human and murine tumors. Int J Cancer 58: 877–881.
28. Sidenius N, Sier CF, Blasi F (2000) Shedding and cleavage of the urokinase
receptor (uPAR): identification and characterisation of uPAR fragments in vitro
and in vivo. FEBS Lett 475: 52–56.
29. Wahlberg K, Hoyer-Hansen G, Casslen B (1998) Soluble receptor for urokinase
plasminogen activator in both full-length and a cleaved form is present in high
concentration in cystic fluid from ovarian cancer. Cancer Res 58: 3294–3298.
30. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, et al. (2002)
Prognostic significance of soluble urokinase plasminogen activator receptor in
serum and cytosol of tumor tissue from patients with primary breast cancer. Clin
Cancer Res 8: 1132–1141.
31. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, et al. (2006)
Enhanced discrimination of benign from malignant prostatic disease by selective
measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52:
838–844.
32. Almasi CE, Christensen IJ, Hoyer-Hansen G, Dano K, Pappot H, et al. (2011)
Urokinase receptor forms in serum from non-small cell lung cancer patients:
relation to prognosis. Lung Cancer 74: 510–515.
33. Almasi CE, Brasso K, Iversen P, Pappot H, Hoyer-Hansen G, et al. (2011)
Prognostic and predictive value of intact and cleaved forms of the urokinase
plasminogen activator receptor in metastatic prostate cancer. Prostate 71: 899–
907.
34. Almasi CE, Drivsholm L, Pappot H, Hoyer-Hansen G, Christensen IJ (2013)
The liberated domain I of urokinase plasminogen activator receptor–a new
tumour marker in small cell lung cancer. APMIS 121: 189–196.
35. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, et al. (2010) A new
assay for measurement of the liberated domain I of the urokinase receptor in
plasma improves the prediction of survival in colorectal cancer. Clin Chem 56:
1636–1640.
36. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, et
al. (1999) Plasma urokinase receptor levels in patients with colorectal cancer:
relationship to prognosis. J Natl Cancer Inst 91: 869–874.
37. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, et al.
(1997) ELISA determination of soluble urokinase receptor in blood from healthy
donors and cancer patients. Clin Chem 43: 1868–1876.
38. Taubert H, Wurl P, Greither T, Kappler M, Bache M, et al. (2010) Co-detection
of members of the urokinase plasminogen activator system in tumour tissue and
serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Br J Cancer 102: 731–737.
39. Nurmenniemi S, Sinikumpu T, Alahuhta I, Salo S, Sutinen M, et al. (2009) A
novel organotypic model mimics the tumor microenvironment. Am J Pathol
175: 1281–1291.
40. Lindberg P, Larsson A, Nielsen BS (2006) Expression of plasminogen activator
inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early
coordinated event in incipient oral squamous cell carcinoma. Int J Cancer
118: 2948–2956.
41. Schultz-Hector S, Haghayegh S (1993) Beta-fibroblast growth factor expression
in human and murine squamous cell carcinomas and its relationship to regional
endothelial cell proliferation. Cancer Res 53: 1444–1449.
42. Teppo S, Sundquist E, Vered M, Holappa H, Parkkisenniemi J, et al. (2013) The
hypoxic tumor microenvironment regulates invasion of aggressive oral
carcinoma cells. Exp Cell Res 319: 376–389.
43. Lund LR, Ellis V, Ronne E, Pyke C, Dano K (1995) Transcriptional and post-
transcriptional regulation of the receptor for urokinase-type plasminogen
activator by cytokines and tumour promoters in the human lung carcinoma
cell line A549. Biochem J 310 (Pt 1): 345–352.
44. Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-PAR): an
essential player in multiple games of cancer: a review on its role in tumor
progression, invasion, metastasis, proliferation/dormancy, clinical outcome and
minimal residual disease. Cell Cycle 5: 1760–1771.
45. Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, et al. (1996) Modulation
of the receptor for urokinase-type plasminogen activator in macrophage-like
U937 cells by inflammatory mediators. Inflammation 20: 319–326.
46. Lund LR, Dano K (1992) Okadaic acid strongly increases gene transcription,
mRNA and protein level for the urokinase receptor in human A549 cells. FEBS
Lett 298: 177–181.
Stromal Induced uPAR Expression
PLOS ONE | www.plosone.org 15 August 2014 | Volume 9 | Issue 8 | e105929
47. Leef G, Thomas SM (2013) Molecular communication between tumor-
associated fibroblasts and head and neck squamous cell carcinoma. Oral Oncol
49: 381–386.
48. Moserle L, Casanovas O (2013) Anti-angiogenesis and metastasis: a tumour and
stromal cell alliance. J Intern Med 273: 128–137.
49. Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated
immune cells. J Mol Med (Berl) 91: 411–429.
50. Siren V, Myohanen H, Vaheri A, Immonen I (1999) Transforming growth
factor beta induces urokinase receptor expression in cultured retinal pigment
epithelial cells. Ophthalmic Res 31: 184–191.
51. Henic E, Sixt M, Hansson S, Hoyer-Hansen G, Casslen B (2006) EGF-
stimulated migration in ovarian cancer cells is associated with decreased
internalization, increased surface expression, and increased shedding of the
urokinase plasminogen activator receptor. Gynecol Oncol 101: 28–39.
52. Gonias SL, Gaultier A, Jo M (2011) Regulation of the urokinase receptor (uPAR)
by LDL receptor-related protein-1 (LRP1). Curr Pharm Des 17: 1962–1969.
53. Engelholm LH, Ingvarsen S, Jurgensen HJ, Hillig T, Madsen DH, et al. (2009)
The collagen receptor uPARAP/Endo180. Front Biosci 14: 2103–2114.
54. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M (2010) Structure-based
engineering of species selectivity in the interaction between urokinase and its
receptor: implication for preclinical cancer therapy. J Biol Chem 285: 10982–
10992.
55. Ploug M, Rahbek-Nielsen H, Nielsen PF, Roepstorff P, Dano K (1998)
Glycosylation profile of a recombinant urokinase-type plasminogen activator
receptor expressed in Chinese hamster ovary cells. J Biol Chem 273: 13933–
13943.
56. Moller LB, Pollanen J, Ronne E, Pedersen N, Blasi F (1993) N-linked
glycosylation of the ligand-binding domain of the human urokinase receptor
contributes to the affinity for its ligand. J Biol Chem 268: 11152–11159.
57. Ragno P, Montuori N, Covelli B, Hoyer-Hansen G, Rossi G (1998) Differential
expression of a truncated form of the urokinase-type plasminogen-activator
receptor in normal and tumor thyroid cells. Cancer Res 58: 1315–1319.
58. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, et al. (1990) The human
receptor for urokinase plasminogen activator. NH2-terminal amino acid
sequence and glycosylation variants. J Biol Chem 265: 6453–6460.
59. Montuori N, Rossi G, Ragno P (1999) Cleavage of urokinase receptor regulates
its interaction with integrins in thyroid cells. FEBS Lett 460: 32–36.
60. Nieves EC, Manchanda N (2010) A cleavage-resistant urokinase plasminogen
activator receptor exhibits dysregulated cell-surface clearance. J Biol Chem 285:
12595–12603.
61. Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation–potential
for therapeutics and diagnostics. Nat Rev Drug Discov 4: 477–488.
62. Jo M, Thomas KS, Wu L, Gonias SL (2003) Soluble urokinase-type
plasminogen activator receptor inhibits cancer cell growth and invasion by
direct urokinase-independent effects on cell signaling. J Biol Chem 278: 46692–
46698.
63. Piccolella M, Festuccia C, Millimaggi D, Locatelli A, Bologna M, et al. (2008)
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits
human prostate cancer cell growth and invasion. Int J Oncol 32: 185–191.
64. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010)
Guidelines for the welfare and use of animals in cancer research. Br J Cancer
102: 1555–1577.
65. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012) Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal
research. Osteoarthritis Cartilage 20: 256–260.
66. Bitu CC, Kauppila JH, Bufalino A, Nurmenniemi S, Teppo S, et al. (2013)
Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo
and in vitro. PLoS One 8: e70925.
67. Lou E, Kellman RM, Hutchison R, Shillitoe EJ (2003) Clinical and pathological
features of the murine AT-84 orthotopic model of oral cancer. Oral Dis 9: 305–
312.
68. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M (1988) Novel purification of
vitronectin from human plasma by heparin affinity chromatography. Cell Struct
Funct 13: 281–292.
69. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
70. Hadler-Olsen E, Kanapathippillai P, Berg E, Svineng G, Winberg JO, et al.
(2010) Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and
ethanol fixation preserve enzyme activity. J Histochem Cytochem 58: 29–39.
71. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric
sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850–
858.
Stromal Induced uPAR Expression
PLOS ONE | www.plosone.org 16 August 2014 | Volume 9 | Issue 8 | e105929
